(BMRN) BioMarin Pharmaceutical Headquarters


Biotechnological devices and products from are made to the ones who need them in certain businesses and firms. International biotech labs and subsidiaries with their subsequent product pipeline are integrated in order to deliver the needed demands in the market. Mentioning one of the key players in here is the BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical Inc. is a company that specialises in the biotech industry. Based in their corporate headquarters in San Rafael, California, it has several locations and offices worldwide. The company’s main business is in enzyme replacement therapies (ERTs). In addition, they were the first biotech company which provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). Also, they were the first proponents to provide therapeutics for phenylketonuria (PKU). The BioMarin pharmaceutical stock is available publicly as well and is open for internship.

BioMarin Pharmaceutical Inc. Headquarters Address

Traded as (BMRN Stock) NASDAQ: BMRN
Industry focused Biotechnology
Founded in 1997
Founder Jean-Jacques Bienaime, Henry J. Fuchs, Dan Spiegelman
Headquarters/Based in San Rafael, CA, USA
Products Biotechnological products


  • Address Location: 770 Lindaro Street, San Rafael, CA 94901, USA
  • Contact number: 415-506-6700
  • Website: http://www.bmrn.com

BioMarin Pharmaceutical Subsidiaries

  • Prosensa
  • BioMarin Europe Ltd.
  • BioMarin International Ltd.
  • Huxley Pharma.

BioMarin Pharmaceutical Inc. Profile/Overview

  • In 1997, BioMarin was founded by men named Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and successfully went public in 1999. Other proponents were MPM Bioventures, Grosvenor Fund and Florian Schönharting. In 2002, BioMarin made an acquisition to Glyko Biomedical.
  • In 2009, another acquisition was made to Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, marketing approval was granted to the company by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert-Eaton myasthenic syndrome (LEMS). BioMarin made a product launch of this under the name Firdapse.
  • In 2010, BioMarin made another acquisition to LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers.
  • In 2012, the company made acquisition to Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
    In November 2014, the company successfully acquired Prosensa for up to $840 million, the range of treatments for Duchenne Muscular Dystrophy however failed to attain FDA approval and in May 2016 development ceased.

BioMarin Pharmaceutical Inc. Products/Capabilities

  • BioMarin Pharmaceutical Inc. is dedicated in the successful development and commercialization of pharmaceuticals for serious diseases and medical conditions worldwide. Its commercial products include the following:
  1. Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease
  2. Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease
  3. Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI
  4. Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder.
  • Clinical trial candidates of BioMarin include:
  1. Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease
  2. pegvaliase, an enzyme substitution therapy for the treatment of PKU
  3. vosoritide, a peptide therapeutic for the treatment of achondroplasia
  4. BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A
  5. BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

(BDX) Becton, Dickinson and Company Headquarters


Medical equipment are made to dedicate them to potential customers and firms. Certain creations and acquisitions are being made especially in the health care and their corresponding human resources. Mentioning one of the key players in this industry is the Becton, Dickinson and Company.

Becton, Dickinson and Company (BD) is a MedTech corporation based in the United States that makes and sells medical devices, instrument systems, and other related products. Founded in 1897 and corporate in Franklin Lakes, New Jersey, the company has 50,000 people working in more than 50 locations in countries internationally. In fiscal year ending of September 30, 2009, more than half of BD sales were generated from non-U.S. markets.

Becton, Dickinson and Company Headquarters Address

Traded as (BDX Stock) NYSE: BDX
Industry focused Medical equipment
Founded in 1897
Founder Maxwell Becton, Fairleigh S. Dickinson
Headquarters/Based in BD HQ, Franklin Lakes, NJ, USA
Products Medical utility and equipment


  • Address location: #1 Becton Drive, Franklin Lakes, NJ 07417, U.S.A.
  • Phone number: 201-847-6800
  • Website: http://www.bd.com


  • CareFusion
  • Accuri Cytometers Inc.
  • PharMingen
  • Becton Dickinson A
  • Becton Dickinson and more.

Key People/Executives for Becton, Dickinson and Company

Mr. Vincent A. Forlenza Chairman and Chief Executive Officer
Mr. Thomas E. Polen Jr. President
Mr. Christopher R. Reidy Chief Financial Officer, Chief Admin. Officer and Executive VP
Mr. Alexandre Conroy Executive VP and Pres of Europe, EMA and the Americas
Dr. Ellen R. Strahlman M.D., M.H.Sc. Chief Medical Officer and Executive Vice President of BD R&D

Becton, Dickinson and Company Profile/Overview

  • Maxwell W. Becton and Fairleigh S. Dickinson were the proponents of the company in 1897, two American businessmen who met on a sales trip. In the same year of first sales, a Luer-all-glass syringe that sold for an amount of $2.50. In 1898, the first patent for a medical product was acquired. In 1899 initial design of logo was created in which was meant to symbolize guaranteed superior quality of the products provided by the company.
  • In 1948, the next generation of Fairleigh S. Dickinson, Jr. and Henry P. Becton, sons of the founders, led the BD. Their term was a time of rapid development for BD. The company generally grew within the U.S. as well as internationally.
  • In 1973, another U.S. facility was added by BD—a research center in Durham, North Carolina in Research Triangle Park. It was built to help meet United States Environmental Protection Agency (EPA) requirements, research improved manufacturing and process methods, and develop future innovative technologies.
  • In 1999, as BD exists for more than a century, it was announced that BD has its new corporate identity. Later then it was shortened to BD.
  • The notable year of ’06 was to document BD’s growth as the acquisition was done to GeneOhm Sciences—a leader in the development of molecular diagnostic testing for the rapid detection of bacterial organisms and TriPath Imaging—a cancer diagnostics company.

Becton, Dickinson and Company Products/Capabilities

Becton, Dickinson and Company is dedicated to bring medical products internationally. It operates in two segments. They are:

  1. BD Medical – This segment offers products such as syringes, pen needles, and IV sets for diabetes; and intravenous catheters for medication delivery of needles, syringes,; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; intravenous medication safety and infusion therapy delivery.
  2. BD Life Sciences – The BD Life Sciences segment provides systems for specimen acquisition processes; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; tests for molecular specimen systems for infectious diseases and women’s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation, and plated media products.

BAX (NYSE): Baxter International Inc. | Headquarters


There is a steadily-increasing demand for equipment in the medical industry. Certain firms are clamouring for more. One of the most recognized companies out there is the Baxter International Inc.

Baxter International Inc. is an international medical company that is listed in the Fortune 500 with locations and stocks around the world. Based on their corporate office in Deerfield US, it mainly focuses on healthcare and products to treat various diseases and inflammations such as hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company had overall sales in 2013 of $16.3 billion, across two businesses such as BioScience and Medical Products.

Baxter International Inc. Headquarters Address

Traded as (BAX Stock) NYSE: BAX
Industry focused Medical equipment
Founded in 1931
Founder Jose E. Almeida, Jay Saccaro
Headquarters/Based in Deerfield, Illinois, USA
Products Medical products primarily to treat hemophilia


  • Address location: One Baxter Pkwy, Df2-1W Deerfield 60015-4625 United States USA
  • Phone number/contact information: 224-948-2000
  • Website: www.baxter.com


  • Gambro
  • Baxter World Trade Corporation
  • Baxter India Private Ltd.
  • Baxter Pharmaceutical Solutions LLC
  • Baxter Polska Sp. z o.o.
  • Claris Lifesciences
  • Baxter Healthcare Ltd. and more.

Key People/Executives for Baxter International Inc.

Mr. José E. Almeida Chairman, Chief Exec. Officer and Pres
Mr. James K. Saccaro Chief Financial Officer and Exec. VP
Mr. Brik V. Eyre Sr. VP and Pres of Americas
Mr. Giuseppe Accogli Sr. VP and Pres of Global Bus.es
Mr. David P. Scharf Consultant

Baxter International Inc. Profile/Overview

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.

Baxter International Inc. Products/Capabilities

  • Baxter International Inc. provides a portfolio of a wide range of renal and hospital products. The company operates through product pipelines of two segments:
  1. Hospital Products – This segment is responsible for manufacturing intravenous or IV solutions and administration sets, V nutrition products, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, Iparenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies.
  2. Renal products – The Renal segment is responsible for the provision of products intended to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services.

(AZN) AstraZeneca Headquarters


Pharmaceutical and biotech companies are dedicated to give quality possible product and service quality to its customers and potential ventures. International medications and pharmaceuticals together with their subsidiaries are integrated in order to deliver the demands. Mentioning one of the key players in the pharmaceutical and biotechnology industry is the AstraZeneca.

AstraZeneca plc is a pharmaceutical and bio-pharmaceutical company based on the nature of an Anglo–Swedish multination. HQ and office locations was transferred to Cambridge, England in 2013, and concentrated its R&D and AstraZeneca pipeline in the following sites: Cambridge; Gaithersburg, Maryland which is the location of MedImmune for bio-pharma work and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs (like diabetes drugs). Consideration as the eighth-largest drug company in the world based on sales revenue was given in the year of 2015.

AstraZeneca Headquarters Address

Traded as (AZN Stock) LSE: AZN
Industry focused Pharmaceutical and biotechnology
Founded in April 6, 1999 in Cambridge, England
Founder Leif Johannson, Pascal Soriot
Headquarters/Based in Cambridge, England
Products Branded and generic pharmaceutical products, biotech products



  • MedImmune

MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer. Major phase III trials include.

durvalumab (anti-PD-L1) benralizumab (anti-IL-5R)
tremelimumab (anti-CTLA-4) tralokinumab (anti-IL-13)
moxetumomab pasudotox (anti-CD22) anifrolumab (anti-IFN-aR)

Key People/Executives for AstraZeneca

Mr. Pascal Soriot CEO & Exec. Director
Mr. Marc Dunoyer CFO & Exec. Director
Ms. Pam P. Cheng Exec. Vice-Pres of Operations and Information Technology
Mr. Jefrey Pott Gen. Counsel
Ms. Katarina Ageborg Chief Compliance Officer

AstraZeneca Profile/Overview

  • In 1913, Astra AB was initially founded in Södertälje, Sweden, by 400 doctors and apothecaries. In 1993 Demerging of pharmaceuticals businesses and its agrochemicals and specialties businesses was done by the British chemicals company ICI, to form Zeneca Group plc. Eventually in the year of 1999 merging of Astra and Zeneca Group was commenced to form AstraZeneca plc, with its headquarters in London.
  • In 2002, Irresa, a drug based in Japan, was approved as monotherapy for the condition of non-small cell lung cancer. On 3 January 2004, a management team of ZI Medical was formed by Dr. Robert Nolan, a former director of AstraZeneca.
  • In July 2017, the company’s CEO Pascal Soriot said that Brexit would not affect its commitment to its current plans in the United Kingdom. However, it had slowed decision making for new investment projects waiting for post-Brexit regulatory regime to settle down.

AstraZeneca Products/Capabilities

AstraZeneca PLC is dedicated to the overall discovery, development, manufacture, and commercialization of prescription medicines for immuno oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases in the international market.

  • Its marketed products for oncology diseases comprise the following:
Arimidex Lynparza
Casodex/Cosudex Nolvadex
Faslodex Tagrisso
Iressa  Zoladex
  • Its marketed products for cardiovascular diseases comprise the following:
Atacand1/Atacand HCT/Atacand Plus Plendil
Brilinta/Brilique Seloken/Toprol-XL
Crestor  Tenormin
Imdur  Zestril
  • Its marketed products for metabolic diseases comprise the following:
Bydureon Onglyza
Byetta Symlin
Farxiga/Forxiga Xigduo
Kombiglyze XR Xigduo XR
  • AstraZeneca’s marketed products for respiratory diseases comprise the following:
Accolate Eklira Genuair/Tudorza Pressair
Bevespi Aerosphere Oxis Turbuhaler
Bricanyl Respules Pulmicort Turbuhaler/Pulmicort Flexhaler
 Bricanyl Turbuhaler Pulmicort Respules
Daliresp/Daxas Symbicort pMDI
Duaklir Genuair Symbicort Turbuhaler
  • AstraZeneca’s marketed products for infection diseases comprise the following:
  1. Fluenz Tetra/FluMist Quadrivalent
  2. Synagis
  • AstraZeneca’s marketed products for neuroscience diseases comprise the following:
  1. Movantik/Moventig
  2. Seroquel IR
  3. Seroquel XR
  4. Vimovo1
  5. Zomig
  • AstraZeneca’s marketed products for gastrointestinal diseases comprise the following:
  1. Losec/Prilosec
  2. Nexium

Primary care and specialty care physicians through distributors and local representative offices are beign served by AstraZeneca. Their pipeline products include 132 projects, of which 120 are in the clinical phase of development.

Align Technology, Inc. Headquarters Office


Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case).

The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services.

What is Align Technology, Inc.?

Known for its industry-leading innovative products, Align Technology, Inc. is a leading global health care service company that pioneers in developing technology-rich products not just in its OrthoCad digital services, but also in its Invisalign clear aligners, and iTero Intraoral scanners which help the patients achieve impressive clinical results. Likewise, it helps the dental professionals in delivering plausible and advanced dental options to their patients.

Alexion Pharmaceuticals Headquarters Address

Traded as NASDAQ: ALGN
Industry focused Pharmaceutical
Founded in 1992
Founder Leonard Bell
Headquarters/Based in New Haven, Connecticut, U.S.
Products Orthodontics devices

Align Technology, Inc. Contacts

  • Location: Align Technology Inc 2560 Orchard Pkwy SAN JOSE 95131-1033 United States USA
  • Phone number number: +1 (408) 738-1500
  • Fax: +1 (408) 470-1010
  • Website: www.aligntech.com/

Products and Services

  • Align Technology, Inc. operates through two segments:
  1. Clear Aligner segment
    This prominent segment of Align Tech, Inc. consists of Invisalign System. This includes its comprehensive products such as Invisalign Full, Teen and Assist and non-comprehensive products such as Express/Lite and Vivera Retainers, together with its training and ancillary products for treating malocclusion (Non-Case).
  2. Scanner and Services (Scanner) segment
    The Scanner and Services (Scanner) segment of Align Tech consists of intra-oral scanning systems, which provide digital alternatives to the traditional cast models. Among these scanners are its notable iTero scanners and OrthoCAD services.

Align Technology, Inc. Principal Subsidiaries

  • Align Technology Japan, Inc.
  • Align Technology, B.V., the Netherlands
  • Align Technology, Ltd.
  • Aligntech de Mexico, S. de R.L. de C.V.
  • Cadent Holdings, Inc.
  • ICA Ortho Services Pte. Ltd.

ALXN (NASDAQ): Alexion Pharmaceuticals | Headquarters


Alexion Pharmaceuticals, Inc. is a pharmaceutical company that aims to enhance and provide revitalized therapies for patients with life-threatening and rare diseases. It has been its goal to discover and develop medical breakthroughs in biologic therapeutic products that are aimed at treating patients with rare, life-threatening diseases, including cancer and autoimmune disorders, hematologic, kidney and neurologic diseases, and transplant rejections.

Alexion Pharmaceuticals was established in 1992 in New Haven, Connecticut. But it was in 1996 that it became a public company (NASDAQ:ALLXN). In 1998, it began the first in-human clinical trial for eculizumab. And in 2007, Alexion’s eculizumab was sold under the trade name Soliris which was approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of patients with paroxysmal nocturnal haemoglobinuri (PNH). Throughout the years, many other breakthroughs and milestones in the field of treating life-threatening diseases were accomplished by Alexion. Also, it was able to acquire Synageva BioPharma, which strengthened its pipeline in establishing a metamorphic franchise with the addition of Kanuma, which was approved as a treatment for patients with hypophosphatasia (HPP)

It was added to the NASDAQ-100 Index in 2011, and only a year after, to the Standard & Poor’s 500 Index. As of 2017, Alexion Pharmaceuticals shares are mostly held by institutional investors (Fidelity Investments, T. Rowe Price, BlackRock and others).

Alexion Pharmaceuticals Headquarters Address

Traded as NASDAQ: ALXN
Industry focused Pharmaceutical
Founded in 1992
Founder Leonard Bell
Headquarters/Based in New Haven, Connecticut, U.S.
Products Branded and generic pharmaceutical products

Alexion Contacts

  • Location: Alexion Pharmaceuticals Inc. 100 College St. NEW HAVEN 06510-3210 United States USA
  • Phone number number: +1 (203) 272-2596
  • Fax: +1 (203) 271-8198
  • Website: www.alxn.com/

Products and Services

Alexion delivers life-changing therapies for patients with life-threatening and rare metabolic disorders: Kanuma (sebelipase alfa) and Strensiq (asfotase alfa). Kanuma is for the treatment of patients with lysosomal acid lipase deficiency (LAL-D), while Strensiq is especially made for patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)

Alexion developed Eculizumab, sold under the trade name Soliris, which is used in the treatment of two chronic, rare diseases caused by an uncontrolled activation of a branch of the immune system called the complement system. These diseases are paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is likewise approved in the European Union for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Key People/Executives for Alexion Pharmaceuticals

David Richard Brennan Chairman
Dr. Ludwig N. Hantson Ph.D. Chief Executive Officer & Director
Ms. Julie O’Neill M.B.A. Executive VP of Global Operations
Dr. David John Anderson M.B.A. Sr. Adviser to the Chief Executive Officer
Mr. Paul L. Clancy M.B.A CFO and Chief Executive VP
Daniel A Bazarko CPA Chief Accounting Officer and Sr. VP

Alexion Pharmaceuticals, Inc. Subsidiaries

Alexion Delaware Holding LLC Alexion Europe SAS
Alexion Cambridge Corporation Alexion Pharma France
Alexion Bermuda L.P.   Alexion Pharma Germany GmbH
 Alexion Holding B.V. Alexion Pharma Israel Ltd.
Alexion Pharma International Sarl Alexion Pharma Italy Sarl
 Alexion Pharma Argentina SRL Alexion Pharma GK
Alexion Pharmaceuticals Australasia PTY LTD Alexion Pharma Mexico, S. de R.L. de C.V.
 Alexion Pharma Belgium Sarl  Alexion Pharma Spain S.L.
 Ltda. (doing business as Alexion Latina America)  Alexion Medical Services Sarl
Alexion Pharma Canada Corp. Alexion İlaç Ticaret Limited Şirketi
Alexion Pharma Colombia SAS  Alexion Pharma UK


When Soliris, an Alexion-pioneered pharmaceutical product, was first approved in March 2007, the company’s peak annual sales were estimated at $150 million. And by September 2013, quarterly sales of Soliris went up to $400 million. Sales during the first quarter of 2015 were over US$600 million. And as of the first quarter of 2017, Alexion’s total revenues is already worth $870 Million, a 24% increase and 26% volume increase year-over-year
Before Alexion’s announcement of the Synageva BioPharma purchase amounting to $8.4 billion, the company was valued at $34 billion. In the last five years, it saw an increase in stock up to 800% and is currently trading at 46 times estimated earnings. The niche nature of its market as well as the high cost of Soliris, its key revenue driver, enabled the company a high-profit margin.

AGN: Allergan Plc. Headquarters Office


Pharmaceutical companies are highly dedicated in giving quality possible product and service quality to its customers and potential ventures. World pharmaceuticals and labs are integrated in order to deliver the demands. Mentioning one of the key players in the pharmaceutical and medical industry is the Allergan.

Allergan, Plc is a multi-national pharmaceutical public limited company that focuses on dermatology, research on pharmaceuticals in the skin, contact, eye, general health, and more. This company produces branded and generic drugs, and performs research and development in the pharmaceutical sector. Initally formed on the date of February 18, 2015, before when the company formerly known as Actavis, Plc changed its name which was completed as of June 15, 2015. Actavis, Plc eventually became Actavis which now forms the AmGen division of the company.

Allergan Headquarters Address

Traded as (AGN Stock) NYSE: AGN
Industry focused Pharmaceutical
Founded in 2015 (by Actavis, PLC’s acquisition)
Founder Allen Chao, Ph. D. & David Hsia, Ph. D.
Headquarters/Based in Dublin, Ireland & Parsippany, Troy Hills, NJ, USA.
Products Branded and generic pharmaceutical products


  • Clonshaugh (Business and Technology Park) B&T Coolock Dublin D17 E400, Ireland
  • Phone number/customer service number: 862 261 7000
  • Website: www.allergan.com

Key People/Executives for Allergan

Mr. Brenton L. Saunders J.D. Chairman, Chief Executive Officer and President
Ms. Maria Teresa Hilado Chief Financial Officer and Executive Vice President
Mr. Robert A. Stewart Executive Vice President & Chief Operating Officer
Mr. William Meury Chief Commercial Officer and Executive Vice President
Mr. James C. D’Arecca Chief Accounting Officer and Vice President

Allergan Products

Allergan plc, is highly dedicated to develop, market, manufacture and distribute medical aesthetics, biosimilar, and over-the-counter pharmaceutical products internationally. It operates through the following categorical segments:

  1. US Specialized Therapeutics
  2. US General Medicine
  3. International segments
  • The company offers a portfolio (product pipeline) of products that provide treatment for the following:
    1. Central nervous system
    2. Gastroenterology
    3. Women’s health, cosmetic and urology
    4. Ophthalmology
    5. Neurosciences
    6. Medical aesthetics
    7. Dermatology
    8. Plastic surgery
    9. Liver disease
    10. Inflammation
    11. Metabolic syndromes
    12. Fibrosis, alzheimer’s disease.
  • It is also involved in other medical developments such as:
    1. Developing ocular implants that reduce intraocular pressure associated with glaucoma
    2. Medical devices for the correction of prominent ears
    3. Intranasal neurostimulation devices, as well as other dry eye products
  • In addition, the medical manufacturing company distributes tangible products such as generic and branded pharmaceutical products primarily to the following recipients or locations:
    1. Independent and chain pharmacies
    2. Nursing homes
    3. Mail order pharmacies
    4. Hospitals
    5. Clinics
    6. Physician offices

AmerisourceBergen 1300 Morris Drive Chesterbrook, PA 19087


Pharmaceutical products and services are provided by companies that are dedicated to its people. Pharmaceutical companies form merges and are strategically integrated in order to deliver the demands in the international market. One of the main players in the pharmaceutical industry is the AmerisourceBergen Corporation.

AmerisourceBergen Corporation (referred to as ABC AmeriSource) is a drug company based in the USA that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. Corporate headquarters of the AmerisourceBergen group are in subsidiaries and locations (HQ) in the US, mainly in Pennsylvania. Drug distribution specialty in their distribution centers and related services designed to reduce costs and improve patient outcomes, distribute a range of brand name and generic pharmaceuticals, over-the-counter (OTC) health care products and home health care supplies and equipment to a wide variety of health care providers located throughout the United States are provided by the company. Provision of pharmaceuticals and pharmacy services to long-term care, workers’ compensation, HR portals and specialty drug patients are also practised.

AmerisourceBergen Corporation Headquarters Address

Traded as (ABC Stock) NYSE: ABC
Industry focused Pharmaceutical
Founded in 2001 (by merging of AmeriSource Health and Bergen Brunswig)
Founder Richard C. Gozon & Steven H. Collis
Headquarters/Based in Chesterbrook, Pennsylvania, USA
Products Pharmaceutical products and services


  • 1300 – Morris Drive, Chesterbrook, Pennsylvania 19087, USA
  • Phone number: 610-727-7000
  • Website/HR Portal: www.amerisourcebergen.com

Key People/Executives for AmerisourceBergen Corporation

Mr. Steven H. Collis Chairman, CEO & President
Mr. Tim G. Guttman CFO & Executive Vice President
Mr. John G. Chou Chief Legal & Bus. Officer & Executive Vice President
Dr. Robert P. Mauch PharmD, Ph.D. Executive Vice President and Group Pres of Pharmaceutical Distribution & Strategic Global Sourcing
Mr. James D. Frary Executive Officer

AmerisourceBergen Corporation Profile/OverviewC

In the year of 2001, the company was initially formed, following the merger of two existing corporations: AmeriSource Health Corporation and Bergen Brunswig Corporation. They were both successful pharmaceutical distributors that served common ventures but covered somewhat different geographies. The said corporate move gave the company a strong national presence that was utilised to the international pharmacies, regional retail chain pharmacies, hospitals and more.

The prosperous company totalled to 26 pharmaceutical distribution centers in the United States alone, nine distribution centers in Canada, four specialty distribution centers in the US, and over 1 million square feet of packaging production space in the US and the UK. Together with the added functionality of the World Courier, the largest specialty courier company in the world, increasing to more than a hundred.

AmerisourceBergen Corporation Products/Capabilities

The AmerisourceBergen Corporation sources and distributes pharmaceutical products in the international market. The company is divided into several segments:

  1. Its Pharmaceutical Distribution (PD) segment distributes the following products:
    1. Brand-name and generic pharmaceuticals
    2. Over-the-counter healthcare products
    3. Home healthcare supplies and equipment
    4. Outsourced compounded sterile preparations
    5. Related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
    6. Pharmacy overall management processes, staffing, and other consulting services
    7. Supply management software to retail and institutional healthcare providers
      packaging solutions to various institutional and retail healthcare providers
    8. Pharmaceutical distribution and other services primarily to medical professionals, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics
    9. Distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products
    10. Offers third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers.
  2. The company’s Other segment is dedicated to provide commercialization support services, including the following specifics:
    1. Reimbursement support programs
    2. Outcomes research
    3. Contract field staffing
    4. Patient assistance and co-pay assistance programs
    5. Adherence programs
    6. Risk mitigation services
    7. Other market access programs to pharmaceutical and biotechnology manufacturers
    8. Specialty transportation and logistics services for the biopharmaceutical industry
    9. Animal health care products.

(NASDAQ: STX) Seagate Technology PLC | Headquarters | Phone number


Computer storage devices established standards for secure, reliable, and high-quality data storage functionality. A vast number of companies are dedicated to producing, selling, and improving computer storage devices to the point that software, IT devices, and even the most reliable hard drives are being produced in a large amount of supplies to meet demands. One highly-regarded data storage company is the Seagate Technology PLC.

Seagate Technology PLC (popularly regarded as simply Seagate) is a data storage company based in the USA. It was incorporated in 1978 under the corporate name of Shugart Technology. Since the year of 2010, the legal Seagate HQ address is in Dublin, Ireland with operational headquarters in Cupertino, California, United States together with several office locations internationally.

Seagate Technology Headquarters Address

Traded as NASDAQ: STX
Industry focused Computer storage industry
Founded in 1979
Founder Alan Shugart, Tom Mitchell, Doug Mahon, Finis Conner and Syed Iftikar
Headquarters/Based in Cupertino, California, United States (operations division) and Dublin, Ireland (legal domicile)
Products Hard disk drives, solid state drives, and hybrid drives


Legal HQ: Thirty-eight/Thirty-nine, Fitzwilliam Square, Dublin 2, Ireland
Operations HQ: Cupertino, California, USA
Contact number: 353 1 234 3136
Website: www.seagate.com

Key People/Executives for Seagate Technology

Mr. Stephen J. Luczo Chairman and CEO
Dr. William David Mosley President and COO
Mr. David H. Morton Jr. Chief Financial Officer and Executive Vice President of Finance
Mr. Patrick J. O’Malley III Senior Vice President
Mr. Philip Gordon Brace President of Cloud Systems & Silicon Group

Seagate Technology Profile/Overview

Seagate is the global leader in data storage solutions, developing amazing products that enable people and businesses around the world to create, share and preserve their most critical memories and business data.

Over the years the amount of information stored has grown from megabytes all the way to geopbytes, confirming the need to successfully store and access huge amounts of data. As demand for storage technology grows the need for greater efficiency and more advanced capabilities continues to evolve.

Today data storage is more than just archiving; it’s about providing ways to analyse information, understand patterns and behaviour, to re-live experiences and memories. It’s about harnessing stored information for growth and innovation. Seagate is building on its heritage of storage leadership to solve the challenge of getting more out of the living information that’s produced everyday. What began with one storage innovation has morphed into many systems and solutions becoming faster, more reliable and expansive. No longer is it just about storing information; it is about accessing and interpreting information quickly, accurately and securely.

Seagate Technology Products/Capabilities

Seagate Technology PLC is dedicated in designing, producing, and distributing electronic data storage technology and solutions worldwide. The company offers the following products:

  1. Hard drives, solid state hybrid drives, SSD, pcie cards, and serial advanced technology architecture controllers for mission critical and nearline applications in enterprise servers and storage systems
  2. Client computing applications, including mobile/desktop computing
  3. Client non-computing applications, such as digital video recorders, personal data backup and portable external storage systems, and digital media and surveillance systems
  4. Several storage subsystems and high performance computing solutions
  5. External backup storage solutions under the Backup Plus and Expansion product lines, as well as under the Maxtor and lacie brands.

Johnson & Johnson Headquarters Office


Pharmaceutical and medical products are one of the most helpful products that humanity had ever been invented and innovated throughout time. Brand establishing is a main thing in big companies in the medical equipment and pharmaceutical industry. One of the main players in the current world is the Johnson and Johnson (or J&J).

Johnson & Johnson is US-based medical equipment and Product Company that is founded in 1886. in New Brunswick, New Jersey while the division in several locations of the CV is being located in Skillman, New Jersey.  The corporation of J&J includes some 250 subsidiary companies with operations in almost a hundred countries and products sold to nearly 200 countries. In the year of 2015, Johnson & Johnson had worldwide sales of a large $70.1 billion.

Johnson & Johnson Headquarters Address

Traded as NYSE: JNJ
Industry focused Medical equipment and pharmaceutical industry
Founded in 1886 in New Brunswick, New Jersey, United States
Founder Robert Wood Johnson I, James Wood Johnson nad Edward Mead Johnson
Headquarters/Based in One Johnson & Johnson Plaza, New Brunswick, New Jersey, United States
Products Pharmaceutical products and various medical equipment


Johnson & Johnson 1 Johnson And Johnson Plz, NEW BRUNSWICK 08933-0001, United States USA
PHONE: +1 (732) 524-2455
FAX: +1 (732) 214-0332
Website: www.jnj.com

Key People/Executives for Johnson & Johnson

Mr. Alex Gorsky Chairman and Chief Exec. Officer
Mr. Dominic J. Caruso Chief Financial Officer and Exec. Vice President
Dr. Paulus A. Stoffels Ph.D., M.D. Chief Scientific Officer and Exec. Vice President
Mr. Joaquin Duato Executive VP & Worldwide Chairman of Pharmaceuticals
Ms. Sandra E. Peterson Exec. Vice President and Group Worldwide Chairman

Johnson and Johnson Profile/Overview

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women’s health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

Johnson and Johnson Products/Capabilities

Johnson & Johnson, develops products in the medical field intenationally. It operates through three segments which are as follows:

  1. Consumer segment
  2. Pharmaceutical segment
  3. Medical Devices segment

The Consumer segment offers the following line of products:

  1. Baby care products (Johnson’s brand); oral care products (Listerine brand)
  2. Beauty products (Aveeno), Clean & Clear, Dabao, Johnson’s Adult, Le Petite Marseillais, Neutrogena, Roc, and OGX brands
  3. Over-the-counter medicines, including acetaminophen products under the Tylenol brand
  4. Cold, flu, and allergy products under the Sudafed brand
  5. Allergy products under the Benadryl and zyrtec brands
  6. Ibuprofen products under the Motrin Ib brand
  7. Acid reflux products under the Pepcid brand.
  8. Women’s health products, such as sanitary pads under the Stayfree and Carefree brands, and tampons under the o.b. Brand
  9. Wound care products comprising brand adhesive bandages under the Band-Aid brand and first aid products under the Neosporin brand.

J&J’s another segment is the pharmaceutical segment. This offers various products in different areas of:

  1. Immunology
  2. Infectious diseases and vaccines
  3. Neurosciences
  4. Oncology
  5. Cardiovascular and metabolic diseases.

The medical devices segment is j&j’s third main segment. It provides the following:

  1. Orthopaedic products
  2. General surgery, endomechanical, biosurgical, and energy products
  3. Electrophysiology products for treatment of cardiovascular disease
  4. Sterilization and disinfection products for surgical infection reduction
  5. Diabetes care products that include blood glucose monitoring and insulin delivery products
  6. Disposable contact lenses to all